Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial-Reference-Cited by-同舟云学术

Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial

Published:2017-10 Issue:10106 Volume:390 Page:1962-1971
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Giugliano Robert P,Pedersen Terje R,Park Jeong-Gun,De Ferrari Gaetano M,Gaciong Zbigniew A,Ceska Richard,Toth Kalman,Gouni-Berthold Ioanna,Lopez-Miranda Jose,Schiele François,Mach François,Ott Brian R,Kanevsky Estella,Pineda Armando Lira,Somaratne Ransi,Wasserman Scott M,Keech Anthony C,Sever Peter S,Sabatine Marc S

Publisher

Elsevier BV

Subject

General Medicine

Reference31 articles.

1. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials;Lancet,2010

2. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines;Grundy;Circulation,2004

3. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1—full report;Jacobson;J Clin Lipidol,2015

4. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 2;Jacobson;J Clin Lipidol,2015

5. 2016 ESC/EAS Guidelines for the management of dyslipidaemias;Catapano;Eur Heart J,2016

Cited by 478 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rationale and design of the effect of evolocumab in patients at high cardiovascular risk without prior myocardial infarction or stroke (VESALIUS-CV) trial;American Heart Journal;2024-03

2. Effective prevention of atherosclerosis by non-viral delivery of CRISPR/Cas9;Nano Today;2024-02

3. Real-World Risk of Recurrent Cardiovascular Events in Atherosclerotic Cardiovascular Disease Patients with LDL-C Above Guideline-Recommended Threshold: A Retrospective Observational Study;Cardiology and Therapy;2024-01-29

4. Long-Term Efficacy and Tolerability of PCSK9 Targeted Therapy: A Review of the Literature;Drugs;2024-01-25

5. From Churchill to Elephants: The Role of Protective Genes against Cancer;Genes;2024-01-18